DexCom cites rising glucose monitor use amid weight loss therapy
JHVEPhoto

DexCom (NASDAQ:DXCM), a maker of continuous glucose monitoring (CGM) systems, traded higher Wednesday after the MedTech company said that use of CGM devices tends to rise in those initiating a class of weight loss drugs called GLP-1 agonists.
Other players in the CGM market, including Abbott (NYSE:ABT), Senseonics Holdings (NYSE:SENS), and Medtronic (NYSE:MDT), are also trading higher.

DexCom (DXCM) shared the results before a Wednesday presentation at the 2023 Wells Fargo Healthcare Conference.
In the investor deck, the company noted that improving access and bringing simplicity to CGM devices can continue to push CGM adoption among all forms of Type 2 diabetes patients, including those on GLP-1s.
In June, Morgan Stanley noted that a broader uptake of weight loss drugs from Novo Nordisk (NVO) and Eli Lilly (LLY), including Novoâs (NVO) FDA-approved GLP-1 agonist Wegovy, can hurt the CGM industry.



More on Abbott, DexCom, etc.

Compare metrics for ABT to DXCM, MDT, SENS
Medtronic: The Crossroads Of Its Growth Trajectory
Medtronic: The Tide Is Turning
Medtronic: Dark Clouds Are Clearing - Outperformance Ahead
Senseonics Faces Headwinds In Competitive CGM Market
Abbott acquires Bigfoot Biomedical, furthers growth of personalized solutions for diabetics
Dexcom G6 strengthens position as worldâs most connected CGM system with a new aid offering in Germany
Abbott a target in proposed baby formula legislation - WSJ
Medtronic gets EU approval for Inceptiv spinal cord stimulator
Medtronic slips as FDA panel votes against blood pressure treatment
Medtronic raises guidance as Q1 results exceed forecasts
Can Medtronic beat negative forecasts with Q1 results?